Matching articles for "azelastine"

Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • January 23, 2023;  (Issue 1668)
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate...
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate (Dymista, and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):12-4 | Show Full IntroductionHide Full Introduction

In Brief: OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • October 31, 2022;  (Issue 1662)
The 0.15% nasal spray formulation of the H1- antihistamine azelastine hydrochloride (Astepro Allergy; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of...
The 0.15% nasal spray formulation of the H1- antihistamine azelastine hydrochloride (Astepro Allergy; Children's Astepro Allergy – Bayer) is now available over the counter (OTC) for temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to allergic rhinitis in adults and children ≥6 years old. It is the first intranasal antihistamine to be approved by the FDA for OTC use. Other drugs that are available OTC for treatment of allergic rhinitis symptoms include oral antihistamines, intranasal corticosteroids, and mast cell stabilizers.
Med Lett Drugs Ther. 2022 Oct 31;64(1662):175-6 | Show Full IntroductionHide Full Introduction

In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022;  (Issue 1650)
The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft...
The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft Once Daily Relief (Allergan) for temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children ≥2 years old. It is the third ophthalmic antihistamine to be approved for over-the-counter (OTC) use (see Table 1).
Med Lett Drugs Ther. 2022 May 16;64(1650):78 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Oral Drugs for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
...
View the Comparison Table: Some Oral Drugs for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e63-5 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2021;  (Issue 1622)
...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
Med Lett Drugs Ther. 2021 Apr 19;63(1622):e66-71 | Show Full IntroductionHide Full Introduction

Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • June 1, 2020;  (Issue 1599)
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic...
A 0.24% ophthalmic solution of the second-generation H1-antihistamine cetirizine (Zerviate – Eyevance) is now available by prescription for treatment of ocular itching associated with allergic conjunctivitis in patients ≥2 years old. Oral cetirizine (Zyrtec, and others), which is used for treatment of allergic conjunctivitis and rhinitis, has been available over the counter (OTC) for years.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):81-3 | Show Full IntroductionHide Full Introduction

OTC Drugs for Seasonal Allergies

   
The Medical Letter on Drugs and Therapeutics • April 22, 2019;  (Issue 1570)
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the...
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):57-60 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • May 8, 2017;  (Issue 1520)
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma.

H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Med Lett Drugs Ther. 2017 May 8;59(1520):71-82 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • May 8, 2017;  (Issue 1520)
...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2017 May 8;59(1520):e85-90 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • May 1, 2013;  (Issue 129)
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their...
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2013 May;11(129):43-52 | Show Full IntroductionHide Full Introduction

Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • October 29, 2012;  (Issue 1402)
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and...
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H1-antihistamine and a corticosteroid.
Med Lett Drugs Ther. 2012 Oct 29;54(1402):85-7 | Show Full IntroductionHide Full Introduction

Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine

   
The Medical Letter on Drugs and Therapeutics • February 8, 2010;  (Issue 1331)
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in...
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Med Lett Drugs Ther. 2010 Feb 8;52(1331):11-2 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • February 1, 2010;  (Issue 90)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83) are prevalent worldwide, especially in...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (not included here; reviewed in Treatment Guidelines 2008; 6:83) are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control these allergic diseases, patients should be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms. Allergen-specific immunotherapy may be useful for treatment of allergic rhinitis and allergic conjunctivitis, and in preventing severe insect venom-triggered reactions.
Treat Guidel Med Lett. 2010 Feb;8(90):9-18 | Show Full IntroductionHide Full Introduction

Azelastine (Astepro) Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • April 20, 2009;  (Issue 1310)
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray (Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old...
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray (Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old and is being heavily advertised to the public on radio, television and the Internet. All azelastine products require a prescription.
Med Lett Drugs Ther. 2009 Apr 20;51(1310):29-30 | Show Full IntroductionHide Full Introduction

Olopatadine (Patanase) Nasal Spray

   
The Medical Letter on Drugs and Therapeutics • June 30, 2008;  (Issue 1289)
Olopatadine 0.6% nasal spray (Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity,...
Olopatadine 0.6% nasal spray (Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin), another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.
Med Lett Drugs Ther. 2008 Jun 30;50(1289):51-2 | Show Full IntroductionHide Full Introduction

Fluticasone Furoate (Veramyst) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • November 5, 2007;  (Issue 1273)
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone...
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.
Med Lett Drugs Ther. 2007 Nov 5;49(1273):90-2 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • August 1, 2007;  (Issue 60)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2007 Aug;5(60):71-80 | Show Full IntroductionHide Full Introduction

Drugs for Some Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • January 1, 2007;  (Issue 53)
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some...
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Treat Guidel Med Lett. 2007 Jan;5(53):1-8 | Show Full IntroductionHide Full Introduction

Epinastine Ophthalmic Solution (Elestat)

   
The Medical Letter on Drugs and Therapeutics • April 26, 2004;  (Issue 1181)
Epinastine HCl, an H1-receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution (Elestat - Allergan/Inspire) for prevention of itching associated with...
Epinastine HCl, an H1-receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution (Elestat - Allergan/Inspire) for prevention of itching associated with allergic conjunctivitis. The drug is available orally in Europe and Asia.
Med Lett Drugs Ther. 2004 Apr 26;46(1181):35-6 | Show Full IntroductionHide Full Introduction

Drugs for Allergic Disorders

   
The Medical Letter on Drugs and Therapeutics • November 1, 2003;  (Issue 15)
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence...
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence during the past 30 years and are now epidemic worldwide, especially in industrialized countries. Many safe and effective drugs are currently available for prevention and relief of symptoms in these disorders, but pharmacological treatment alone may not be sufficient. Patients should also be instructed to avoid specific allergens or environmental conditions that trigger their symptoms. Allergen-specific immunotherapy, parenteral administration of gradually increasing doses of the allergen ("allergy shots"), has been effective in allergic rhinitis, allergic conjunctivitis and allergic asthma, and also in prevention of anaphylaxis triggered by stings from bees, yellow jackets, hornets and wasps. It has not been effective in food allergy, atopic dermatitis or urticaria.
Treat Guidel Med Lett. 2003 Nov;1(15):93-100 | Show Full IntroductionHide Full Introduction

Azelastine Nasal Spray for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • May 9, 1997;  (Issue 1000)
Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray (Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal...
Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray (Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal sprays are also available for this indication (Medical Letter, 37:5, 1995). Cromolyn sodium (Nasalcrom) has now been approved for over-the-counter use.
Med Lett Drugs Ther. 1997 May 9;39(1000):45-7 | Show Full IntroductionHide Full Introduction